Log in

NASDAQ:KNSAKiniksa Pharmaceuticals Earnings Date, Estimates & History

-0.79 (-3.43 %)
(As of 07/13/2020 04:00 PM ET)
Today's Range
Now: $22.25
50-Day Range
MA: $22.80
52-Week Range
Now: $22.25
Volume277,600 shs
Average Volume286,546 shs
Market Capitalization$1.33 billion
P/E RatioN/A
Dividend YieldN/A


Kiniksa Pharmaceuticals (NASDAQ:KNSA) Earnings Information

Kiniksa Pharmaceuticals last issued its quarterly earnings data on April 28th, 2020. The reported ($0.48) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.15. Kiniksa Pharmaceuticals has generated ($2.99) earnings per share over the last year. Kiniksa Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 10th, 2020 based off prior year's report dates.

Kiniksa Pharmaceuticals Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Earnings Estimates

2020 EPS Consensus Estimate: ($2.22)
2021 EPS Consensus Estimate: ($2.42)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20201($0.63)($0.63)($0.63)
Q2 20201($0.50)($0.50)($0.50)
Q3 20201($0.53)($0.53)($0.53)
Q4 20201($0.56)($0.56)($0.56)
Q1 20211($0.60)($0.60)($0.60)
Q2 20211($0.58)($0.58)($0.58)
Q3 20211($0.60)($0.60)($0.60)
Q4 20211($0.64)($0.64)($0.64)

Kiniksa Pharmaceuticals (NASDAQ KNSA) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
2/26/2020Q4 2019($0.62)($0.58)($0.58)N/A
8/12/2019Q2 2019($0.71)($0.6827)($0.68)N/A
5/2/2019Q1 2019($0.80)($1.27)($1.27)N/A
8/6/2018Q2 2018($0.4350)($0.97)($0.97)N/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.